Production (Stage)
Pharming Group N.V.
PHAR
$11.86
$0.64775.78%
NASDAQ
12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
---|---|---|---|---|---|
Revenue | -- | 277.56M | 258.36M | 245.32M | |
Total Other Revenue | -- | -- | -- | -- | |
Total Revenue | -- | 277.56M | 258.36M | 245.32M | |
Cost of Revenue | -- | 31.78M | 29.52M | 25.21M | |
Gross Profit | -- | 245.78M | 228.84M | 220.10M | |
SG&A Expenses | -- | 187.17M | 183.51M | 175.26M | |
Depreciation & Amortization | -- | -- | -- | -- | |
Other Operating Expenses | -- | 19.18M | 19.24M | 19.01M | |
Total Operating Expenses | -- | 310.38M | 303.84M | 288.15M | |
Operating Income | -- | -32.82M | -45.48M | -42.83M | |
Income Before Tax | -- | -15.41M | -11.96M | -12.01M | |
Income Tax Expenses | -- | -2.08M | -1.17M | -1.46M | |
Earnings from Continuing Operations | -- | -13.33 | -10.79 | -10.55 | |
Earnings from Discontinued Operations | -- | -- | -- | -- | |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
Minority Interest in Earnings | -- | -- | -- | -- | |
Net Income | -- | -13.33M | -10.79M | -10.55M | |
EBIT | -- | -32.82M | -45.48M | -42.83M | |
EBITDA | -- | -14.49M | -27.75M | -28.71M | |
EPS Basic | -- | -0.02 | -0.02 | -0.02 | |
Normalized Basic EPS | -- | -0.02 | -0.03 | -0.03 | |
EPS Diluted | -- | -0.02 | -0.02 | -0.02 | |
Normalized Diluted EPS | -- | -0.02 | -0.03 | -0.03 | |
Average Basic Shares Outstanding | -- | 2.71B | 2.69B | 2.68B | |
Average Diluted Shares Outstanding | -- | 2.71B | 2.69B | 2.68B | |
Dividend Per Share | -- | -- | -- | -- | |
Payout Ratio | -- | -- | -- | -- |